One-Day Event Unveiling New Epilepsy Therapies and CNS Market Opportunity to Be Held in San Francisco

Business Wire via NewsEdge Corporation :

Business Editors/Health/Medical Writers

RESTON, Va. (BUSINESS WIRE) January 22, 2008—The Epilepsy Therapy Project (ETP), a non-profit organization dedicated to advancing new therapies for people living with epilepsy, announces the "Epilepsy Pipeline Update: Portal into CNS Opportunities" conference, an in-depth, one-day forum to be held March 13, 2008, at the Hotel Monaco in San Francisco. The conference will feature a line up of leading scientists, innovators, clinical investigators and industry leaders who have been selected to speak on new epilepsy therapies and the broad follow-on opportunities in the CNS market.

The conference will bringtogether emerging CNS companies and scientific entrepreneurs to present their strategies, product candidates and development programs to potential venture capital, private equity, pharma and biotech investors and partners. Hand-selected by the Scientific and Business Advisory Boards of Epilepsy Therapy Project, presenters will cover the most innovative and intriguing therapeutic targets and candidates in development today for epilepsy with potential to be used for broader CNS development. Presentations will review products from public companies such as Abbott, GlaxoSmithKline, Jazz Pharmaceuticals, Pfizer, Ovation Pharmaceuticals and UCB Pharma, as well as private companies such as Icagen, Bio-Link, Marinus Pharmaceuticals, NeuroGenomeX, NeuroPace, Neurologix, NeuroVista, Sierra Pharmaceuticals and Vistagen.

In addition, attendees will hear from renowned neuro-pharmacologist John H. Krystal, M.D., Professor and Deputy Chairman for Research, Yale Department of Psychiatry, who will describe the common pathways by which epilepsy treatments also are effective in other CNS disorders, and Michael A. Rogawski, M.D., Ph.D., Chairman, Department of Neurology, University of California, Davis, who will discuss new CNS drug targets that have emerged from epilepsy models and breakthrough epilepsy treatment strategies currently under investigation. These CNS targets may include conditions such as migraine, depression, neuropathic pain, anxiety and sleep disorders. Speakers will show progress from preclinical models, evolution of understanding in known mechanisms of action to novel approaches, new technology platforms and devices.

"This event is a unique networking opportunity for scientific, clinical, industry and investment thought leaders dedicated to epilepsy drug and device development who share an awareness of broader CNS areas and markets. Epilepsy therapy discovery provides a powerful platform for new product concepts, as well as a natural and well-paved pathway for CNS drug and device development," said Joyce Cramer, President of ETP and research scientist at Yale University School of Medicine. "We also have learned that major CNS scientific and clinical advances are yielding tremendous opportunities for investors and industry, all of which demand a close understanding of product lifecycle management for these novel neuro-therapies."

Business development, industry executives, venture and crossover investors focused on financing and partnering opportunities in the epilepsy and CNS space, as well as those interested in emerging drugs in the epilepsy and CNS pipeline, are invited to attend this comprehensive forum. For registration or additional program information, please visit our conference details page at: http://www.epilepsy.com/etp/epilepsy_pipeline. Note early registration fees will be available until January 31, 2008.

The Epilepsy Therapy Project thanks the supporters of the Epilepsy Pipeline Update conference including Credit Suisse, Bay City Capital, L.E.K. Consulting, Granite Point Capital, UCB Pharma, Jazz Pharmaceuticals, Ovation Pharmaceuticals, Center for Integration of Medicine and Innovative Technology (CIMIT), New York University, and others.

About the Epilepsy Therapy Project

The Epilepsy Therapy Project is a non-profit organization whose mission is to advance new therapies for people living with epilepsy. Founded in 2002 by a group of parents, distinguished physicians and researchers, the Epilepsy Therapy Project supports the commercialization of new therapies through direct grants and investments in promising academic and commercial projects. The organization has raised over six million dollars towards its mission. Learn more at www.epilepsy.com.

Epilepsy Therapy Project
Kim Macher, 703-437-4250
kim@epilepsytherapyproject.org

or

BCC Partners
Susan Pietropaolo,
845-638-6290
spietropaolo@bccpartners.com

State Keywords: California; VirginiaIndustry Keywords: Health; Biotechnology; Clinical Trials; Mental Health; Research; ScienceSource: Epilepsy Therapy Project (ETP)

Our Mission

The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

 
24/7 helpline
P